UBS raised the firm’s price target on Bath & Body Works to $46 from $44 and keeps a Neutral rating on the shares. The firm believes Bath & Body’s sales growth trends are roughly similar to what they were when it last reported on November 16, and thinks this will cause Bath & Body to reiterate its early view of sales growth inflecting positive in the second half of 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BBWI:
- Bath & Body Works Declares Cash Dividend
- Bath & Body Works put volume heavy and directionally bearish
- Bath & Body Works price target raised to $52 from $50 at Morgan Stanley
- Bath & Body Works price target raised to $44 from $34 at UBS
- Bath & Body Works downgraded to Equal Weight from Overweight at Barclays
